DE10024788A1 - Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort - Google Patents

Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Info

Publication number
DE10024788A1
DE10024788A1 DE10024788A DE10024788A DE10024788A1 DE 10024788 A1 DE10024788 A1 DE 10024788A1 DE 10024788 A DE10024788 A DE 10024788A DE 10024788 A DE10024788 A DE 10024788A DE 10024788 A1 DE10024788 A1 DE 10024788A1
Authority
DE
Germany
Prior art keywords
sba
composition according
particles
oil
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10024788A
Other languages
German (de)
English (en)
Inventor
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GERBU GmbH
Pharmasol GmbH
Original Assignee
GERBU GmbH
Pharmasol GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GERBU GmbH, Pharmasol GmbH filed Critical GERBU GmbH
Priority to DE10024788A priority Critical patent/DE10024788A1/de
Publication of DE10024788A1 publication Critical patent/DE10024788A1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE10024788A 1999-05-20 2000-05-19 Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort Ceased DE10024788A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE10024788A DE10024788A1 (de) 1999-05-20 2000-05-19 Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20
DE10024788A DE10024788A1 (de) 1999-05-20 2000-05-19 Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Publications (1)

Publication Number Publication Date
DE10024788A1 true DE10024788A1 (de) 2000-11-23

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10024788A Ceased DE10024788A1 (de) 1999-05-20 2000-05-19 Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Country Status (11)

Country Link
EP (1) EP1183045A2 (tr)
JP (1) JP2003500365A (tr)
KR (1) KR20020012221A (tr)
AU (2) AU5214200A (tr)
BR (1) BR0010823A (tr)
CA (1) CA2373239A1 (tr)
DE (1) DE10024788A1 (tr)
MX (1) MXPA01011660A (tr)
TR (1) TR200103333T2 (tr)
WO (2) WO2000071154A2 (tr)
ZA (1) ZA200109147B (tr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071154A2 (de) * 1999-05-20 2000-11-30 Pharmasol Gmbh Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort
WO2017097783A1 (en) * 2015-12-08 2017-06-15 Glaxosmithkline Biologicals S.A. Novel adjuvant formulations

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
ES2379267T3 (es) * 2003-10-23 2012-04-24 Novartis Vaccines And Diagnostics, Inc. Composiciones estabilizadas
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
US8424518B2 (en) 2008-06-13 2013-04-23 Mannkind Corporation Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5667095B2 (ja) 2009-03-11 2015-02-12 マンカインド コーポレイション 吸入器の抵抗を測定するための装置、システムおよび方法
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
CN103826988B (zh) 2011-04-01 2016-03-09 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CA2906817C (en) 2013-03-15 2022-01-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2016000739A (es) 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
DE10024788A1 (de) * 1999-05-20 2000-11-23 Gerbu Gmbh Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071154A2 (de) * 1999-05-20 2000-11-30 Pharmasol Gmbh Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort
WO2000071154A3 (de) * 1999-05-20 2001-06-28 Pharmasol Gmbh Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort
WO2017097783A1 (en) * 2015-12-08 2017-06-15 Glaxosmithkline Biologicals S.A. Novel adjuvant formulations
BE1024228B1 (fr) * 2015-12-08 2017-12-21 Glaxosmithkline Biologicals Sa Nouvelles formulations d'adjuvants

Also Published As

Publication number Publication date
ZA200109147B (en) 2002-05-08
AU5214200A (en) 2000-12-12
CA2373239A1 (en) 2000-11-30
BR0010823A (pt) 2002-03-05
AU5809100A (en) 2000-12-12
EP1183045A2 (de) 2002-03-06
KR20020012221A (ko) 2002-02-15
WO2000071154A2 (de) 2000-11-30
WO2000071154A3 (de) 2001-06-28
TR200103333T2 (tr) 2002-04-22
WO2000071077A2 (en) 2000-11-30
MXPA01011660A (es) 2004-04-05
JP2003500365A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
DE10024788A1 (de) Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort
Rosada et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
DE69632395T2 (de) Cochleat-abgabevehikel für biologisch relevante moleküle
DE69836429T2 (de) Impstoffe gegen Hepatitis B die Öl in Wasser Emulsionen enthalten
Hansen et al. Nanoparticles for transcutaneous vaccination
DE69836268T2 (de) Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen
EP1051189A2 (de) Vakzinformulierungen
CN1980638B (zh) 用糖脂稳定基于脂质的佐剂制剂的组合物和方法
Cosco et al. Colloidal carriers for the enhanced delivery through the skin
DE60002650T2 (de) Öladjuvierter Impfstoff
CH678492A5 (tr)
DE69533693T2 (de) Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
KR20010112252A (ko) 피부통과 비침습성 예방접종
CN102223876A (zh) 纳米乳剂治疗性组合物及其使用方法
DE2362121A1 (de) Adjuvans-zusammensetzungen fuer antigen-praeparate
Bertona et al. Development and assessment of a new cage-like particle adjuvant
US20200405846A1 (en) Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
WO2021208860A1 (zh) 一种基于微乳的疫苗递送系统及其制备方法和应用
DE69910253T2 (de) Verfahren zur herstellung von inaktivierten, w/ö emulsion adjuvierten, impfstoffen
Cevc et al. Deformable (Transfersome®) vesicles for improved drug delivery into and through the skin
CN110139826A (zh) 具有负的表面电荷的微粒和纳米颗粒
DE2603321A1 (de) Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser
EP1420818B1 (en) Antigenic compositions
DE69838324T2 (de) Ph-sensitive liposomen und andere typen immunomodulatoren enthaltender gekapselter impfstoffe sowie herstellungs- und anwendungsverfahren dafür
DE102011018499A1 (de) Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection